NCT04397016

Brief Summary

The purpose of this study is to investigate whether an encounter decision aid (used during a consultation) containing cost information about options, combined with clinician training about cost discussions and available financial resources, influence surgeon-patient cost conversations, referrals to address costs, patients' financial stress, and high-quality decision-making for patients with slow-growing prostate cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
117

participants targeted

Target at P50-P75 for not_applicable prostate-cancer

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 11, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
22 days until next milestone

Study Start

First participant enrolled

June 12, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 2, 2022

Completed
Last Updated

September 26, 2022

Status Verified

September 1, 2022

Enrollment Period

1.9 years

First QC Date

May 11, 2020

Last Update Submit

September 23, 2022

Conditions

Keywords

Prostate CancerTreatment Costs

Outcome Measures

Primary Outcomes (3)

  • Frequency of cost conversations

    Immediately after the clinic or virtual visit

  • Initiator (surgeon, patient, or caregiver) of cost conversations

    Immediately after the clinic or virtual visit

  • Whether or not a referral is made to address costs

    Immediately after the clinic or virtual visit

Secondary Outcomes (2)

  • Number of patients who had a decisional conflict

    Immediately after the clinic or virtual visit

  • Number of patients who engaged in high-quality shared decision-making - CollaboRATE

    Immediately after the clinic or virtual visit

Other Outcomes (3)

  • Decision regret

    3 month follow-up

  • Number of patients who had a decisional conflict

    3 month follow-up

  • Financial toxicity

    3 month follow-up

Study Arms (2)

Arm 1: Usual Care

NO INTERVENTION

* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer. * Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure.

Arm 2: Option Grid

EXPERIMENTAL

* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer. * Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure.

Behavioral: Option Grid Decision Aid

Interventions

-A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions

Arm 2: Option Grid

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years of age
  • Visiting a participating urologist/urologic surgeon to discuss treatment options
  • Slow growing prostate cancer defined as Gleason score of 6 or 7 (3+4) and/or PSA (prostate-specific antigen) level less than 10ng/ml or at surgeon's discretion
  • Must be patients of one of the participating providers

You may not qualify if:

  • Patients who cannot give informed consent due to cognitive or emotional barriers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Publications (2)

  • Politi MC, Forcino RC, Parrish K, Durand MA, O'Malley AJ, Moses R, Cooksey K, Elwyn G. The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: Results of a stepped-wedge cluster randomised trial. Health Expect. 2023 Oct;26(5):2023-2039. doi: 10.1111/hex.13810. Epub 2023 Jul 2.

  • Politi MC, Forcino RC, Parrish K, Durand MA, O'Malley AJ, Elwyn G. Cost talk: protocol for a stepped-wedge cluster randomized trial of an intervention helping patients and urologic surgeons discuss costs of care for slow-growing prostate cancer during shared decision-making. Trials. 2021 Jun 29;22(1):422. doi: 10.1186/s13063-021-05369-4.

Related Links

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Mary Politi, Ph.D.

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR
  • Glyn Elwyn, M.D., Ph.D., MSc

    Dartmouth College

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SEQUENTIAL
Model Details: This is a stepped wedge randomized trial. The intervention condition (the relevant Option Grid decision aid that includes cost information about option) is sequentially assigned to participating surgeons in 4 clusters. By the end of recruitment, all surgeons will have been exposed to the intervention (about 100 surgeon-patient encounters using the Option Grid) and will have provided data for the control (about 100 control cases). Independent eligible patients will be enrolled at each period within a cluster, thus, analyzed as a repeated cross-sectional study. Periods (steps) are set intervals of time. The length of each step is 3 months. Steps 1-3 provide data from both conditions within each cluster (step 0 provides data only from the control while step 4 provides data only from the Option Grid arm) and data is collected from all clusters. Each step will add one clinician to the Option Grid arm.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2020

First Posted

May 21, 2020

Study Start

June 12, 2020

Primary Completion

April 20, 2022

Study Completion

July 2, 2022

Last Updated

September 26, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations